CPD-002 

CPD-002 is an inhibitor for vascular endothelial growth factor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis^[1].

CPD-002 (0-64 μM, 24-48 h) exhibits cytotoxicity for cells HUVECs and MH7A, in a dose-dependent manner^[1].
CPD-002 (0-8 μM, 24 h) inhibits VEGF-induced cell migration and invasion of HUVECs, through suppression of F-actin expression, and chemotactic response to MH7A cell-released chemoattractants^[1].
CPD-002 (0-8 μM) exhibits anti-inflammatory activity through inhibition of the inflammatory mediators like TNF-α, IL-1β, IL-6, IL-8, MMP2 and MMP9, and thus inhibits synovial angiogenesis^[1].
CPD-002 (0-8 μM, 9 days) inhibits HUVECs tube formation and aortic ring sprout formation in ex vivo rat aortic ring assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CPD-002 (15-60 mg/kg, i.p., once daily for 14 days) exhibits anti-arthritic and anti-angiogenic effects in adjuvant-induced arthritisrats rats model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

340.40

C₁₇H₁₆N₄O₂S

2617376-08-4

CNC(C1=CC=CC=C1SC2=CC3=C(C(NC(C)=O)=NN3)C=C2)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jiang F, et al., CPD-002, a novel VEGFR2 inhibitor, relieves rheumatoid arthritis by reducing angiogenesis through the suppression of the VEGFR2/PI3K/AKT signaling pathway. Int Immunopharmacol. 2024 Apr 20;131:111850.   [Content Brief]